Novo Nordisk As Stock Analysis

NVO Stock  USD 134.08  1.96  1.44%   
Novo Nordisk AS is overvalued with Real Value of 89.17 and Target Price of 80.4. The main objective of Novo Nordisk stock analysis is to determine its intrinsic value, which is an estimate of what Novo Nordisk AS is worth, separate from its market price. There are two main types of Novo Nordisk's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Novo Nordisk's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Novo Nordisk's stock to identify patterns and trends that may indicate its future price movements.
The Novo Nordisk stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Novo Nordisk is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Novo Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Novo Nordisk's ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Novo Stock Analysis Notes

The company has Price/Earnings To Growth (PEG) ratio of 2.36. Novo Nordisk AS last dividend was issued on the 22nd of March 2024. The entity had 2:1 split on the 20th of September 2023. Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States. To find out more about Novo Nordisk AS contact Lars Jorgensen at 45 44 44 88 88 or learn more at https://www.novonordisk.com.

Novo Nordisk Quarterly Total Revenue

65.35 Billion

Novo Nordisk AS Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Novo Nordisk's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Novo Nordisk AS or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
The company has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Novo Nordisk until it has trouble settling it off, either with new capital or with free cash flow. So, Novo Nordisk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novo Nordisk AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novo to invest in growth at high rates of return. When we think about Novo Nordisk's use of debt, we should always consider it together with cash and equity.
Novo Nordisk AS has a poor financial position based on the latest SEC disclosures
On 2nd of April 2024 Novo Nordisk paid $ 0.6638 per share dividend to its current shareholders
Latest headline from medcitynews.com: Eli Lilly Pumps 5.3B More Into Site for Making Metabolic Meds Zepbound Mounjaro

Novo Nordisk AS Upcoming and Recent Events

Earnings reports are used by Novo Nordisk to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Novo Nordisk previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
31st of January 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
31st of January 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Novo Largest EPS Surprises

Earnings surprises can significantly impact Novo Nordisk's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2006-10-27
2006-09-300.090.10.0111 
2012-02-02
2011-12-310.260.30.0415 
2020-05-06
2020-03-310.680.750.0710 
View All Earnings Estimates

Novo Nordisk Environmental, Social, and Governance (ESG) Scores

Novo Nordisk's ESG score is a quantitative measure that evaluates Novo Nordisk's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Novo Nordisk's operations that may have significant financial implications and affect Novo Nordisk's stock price as well as guide investors towards more socially responsible investments.

Novo Nordisk Thematic Classifications

In addition to having Novo Nordisk stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Baby Boomer Prospects Idea
Baby Boomer Prospects
Mega stocks, funds and ETFs that tend to appeal to people considering retirement from the work force
Giant Impact Idea
Giant Impact
Public companies with mega capitalization

Novo Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Novo Nordisk is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novo Nordisk AS backward and forwards among themselves. Novo Nordisk's institutional investor refers to the entity that pools money to purchase Novo Nordisk's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Polen Capital2024-03-31
7.8 M
Blackrock Inc2023-12-31
7.3 M
Capital Research & Mgmt Co - Division 32024-03-31
7.1 M
State Street Corporation2023-12-31
6.6 M
Everett Harris & Co2024-03-31
6.5 M
State Farm Mutual Automobile Ins Co2024-03-31
6.1 M
Jpmorgan Chase & Co2023-12-31
4.7 M
Envestnet Asset Management Inc2023-12-31
4.2 M
Wcm Investment Management2024-03-31
4.1 M
Jennison Associates Llc2024-03-31
21.1 M
Renaissance Technologies Corp2023-12-31
13.8 M
Note, although Novo Nordisk's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Novo Market Capitalization

The company currently falls under 'Mega-Cap' category with a total capitalization of 606.01 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novo Nordisk's market, we take the total number of its shares issued and multiply it by Novo Nordisk's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Novo Profitablity

Novo Nordisk's profitability indicators refer to fundamental financial ratios that showcase Novo Nordisk's ability to generate income relative to its revenue or operating costs. If, let's say, Novo Nordisk is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Novo Nordisk's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Novo Nordisk's profitability requires more research than a typical breakdown of Novo Nordisk's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of 0.37 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.49 %, which entails that for every 100 dollars of revenue, it generated $0.49 of operating income.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.33  0.35 
Return On Capital Employed 0.71  0.74 
Return On Assets 0.27  0.14 
Return On Equity 0.79  0.82 

Management Efficiency

Novo Nordisk AS has Return on Asset of 0.2524 % which means that on every $100 spent on assets, it made $0.2524 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.9987 %, implying that it generated $0.9987 on every 100 dollars invested. Novo Nordisk's management efficiency ratios could be used to measure how well Novo Nordisk manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 28th of May 2024, Return On Capital Employed is likely to grow to 0.74, while Return On Assets are likely to drop 0.14. At this time, Novo Nordisk's Return On Tangible Assets are very stable compared to the past year. As of the 28th of May 2024, Intangibles To Total Assets is likely to grow to 0.20, while Non Currrent Assets Other are likely to drop about 1.4 B.
Last ReportedProjected for Next Year
Book Value Per Share 23.77  24.96 
Net Current Asset Value 0.00  0.00 
Tangible Asset Value 0.00  0.00 
Tangible Book Value Per Share 10.30  5.69 
Enterprise Value Over EBITDA 27.84  29.23 
Price Book Value Ratio 29.38  30.85 
Enterprise Value Multiple 27.84  29.23 
Price Fair Value 29.38  30.85 
Enterprise Value3.1 T3.3 T
The analysis of Novo Nordisk's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Novo Nordisk's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Novo Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield
0.0101
Forward Dividend Yield
0.0101
Forward Dividend Rate
1.37
Beta
0.195

Technical Drivers

As of the 28th of May, Novo Nordisk secures the Risk Adjusted Performance of 0.0572, downside deviation of 1.42, and Mean Deviation of 1.26. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novo Nordisk AS, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Novo Nordisk, which can be compared to its peers in the industry. Please verify Novo Nordisk AS jensen alpha and semi variance to decide if Novo Nordisk AS is priced some-what accurately, providing market reflects its recent price of 134.08 per share. Given that Novo Nordisk AS has jensen alpha of 0.1173, we recommend you to check Novo Nordisk's last-minute market performance to make sure the company can sustain itself at a future point.

Novo Nordisk AS Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Novo Nordisk middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Novo Nordisk AS. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Novo Nordisk Predictive Daily Indicators

Novo Nordisk intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Novo Nordisk stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Novo Nordisk Corporate Filings

17th of May 2024
Other Reports
ViewVerify
6K
15th of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
13th of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
6th of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
2nd of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
1st of May 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
26th of April 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
25th of April 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify

Novo Nordisk Forecast Models

Novo Nordisk's time-series forecasting models are one of many Novo Nordisk's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Novo Nordisk's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Novo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Novo Nordisk prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Novo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Novo Nordisk. By using and applying Novo Stock analysis, traders can create a robust methodology for identifying Novo entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.45  0.47 
Operating Profit Margin 0.44  0.46 
Net Profit Margin 0.36  0.38 
Gross Profit Margin 0.85  0.58 

Current Novo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Novo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Novo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
80.4Strong Buy10Odds
Novo Nordisk AS current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Novo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Novo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Novo Nordisk AS, talking to its executives and customers, or listening to Novo conference calls.
Novo Analyst Advice Details

Novo Stock Analysis Indicators

Novo Nordisk AS stock analysis indicators help investors evaluate how Novo Nordisk stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Novo Nordisk shares will generate the highest return on investment. By understating and applying Novo Nordisk stock analysis, traders can identify Novo Nordisk position entry and exit signals to maximize returns.
Begin Period Cash Flow12.7 B
Long Term Debt16 B
Common Stock Shares Outstanding4.5 B
Total Stockholder Equity106.6 B
Tax Provision21 B
Quarterly Earnings Growth Y O Y0.294
Property Plant And Equipment Net91 B
Cash And Short Term Investments30.2 B
Cash14.4 B
Accounts Payable25.6 B
Net Debt12.6 B
50 Day M A128.2852
Total Current Liabilities169.7 B
Other Operating Expenses129.7 B
Non Current Assets Total174.8 B
Forward Price Earnings39.5257
Non Currrent Assets Other1.4 B
Stock Based Compensation2.1 B
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Novo Stock analysis

When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
CEOs Directory
Screen CEOs from public companies around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.294
Earnings Share
2.88
Revenue Per Share
54.605
Quarterly Revenue Growth
0.225
Return On Assets
0.2524
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.